background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

BIFUNCTIONAL
FUSION PROTEIN

Bifunctional fusion proteins bind 2 different molecules, resulting in a functional outcome. A subset of bifunctional fusion proteins includes a novel class of antibody-cytokine fusions that can potentially improve T-cell function and antitumor immunity.1,2

IL-21R, interleukin 21 receptor; PD-1, programmed cell death protein 1.

References
1. Shen S, et al. Front Immunol. 2020;11:832. doi:10.3389/fimmu.2020.00832. 2. Shen S, et al. Poster presented at: Keystone Symposia; March 10–14, 2019; Whistler, BC, Canada. Poster 1006. 3. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 4. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04362748. Accessed 9/10/20.
Molecule
Modality3
Target3
Areas of Investigation4
AMG 256
Modality3
BIFUNCTIONAL
FUSION PROTEIN
Target3
Areas of Investigation4

IL-21R, interleukin 21 receptor; PD-1, programmed cell death protein 1.

References
1. Shen S, et al. Front Immunol. 2020;11:832. doi:10.3389/fimmu.2020.00832. 2. Shen S, et al. Poster presented at: Keystone Symposia; March 10–14, 2019; Whistler, BC, Canada. Poster 1006. 3. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 4. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04362748. Accessed 9/10/20.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.